Gari, Hamid H <br/><br/>
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.  [electronic resource] 

 -  Oncotarget  Mar 2016 
 - 15757-71 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.7462  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Calcitriol--analogs & derivatives<br/>Cell Line, Tumor<br/>Drug Screening Assays, Antitumor--methods<br/>Female<br/>Humans<br/>Neoplasm Proteins--genetics<br/>Oncogenes<br/>Protein Tyrosine Phosphatases--genetics<br/>Triple Negative Breast Neoplasms--genetics<br/>Vitamin D--analogs & derivatives